Journals / Turkish Journal of Biology / 2020 / Cilt: 44 - Sayı: 5

Regulation of E2F1 activity via PKA-mediated phosphorylations

Pages
215–229
Publication Date
2020-10-13
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to our results, PKA-mediated phosphorylation of E2F1 by PKA inhibits proliferation and glucose uptake and induces caspase-3 activation and senescence.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:E2F1 becomes activated during the G1 phase of the cell cycle, and posttranslational modifications modulate its activity.
📊
Key Findings & Data:Since PKA activation negatively regulates cell proliferation, we thought that activated PKA would negatively affect the activity of E2F1.
💡
Conclusion & Impact:According to our results, PKA-mediated phosphorylation of E2F1 by PKA inhibits proliferation and glucose uptake and induces caspase-3 activation and senescence.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:E2F1 · cell cycle · PKA

Abstract

E2F1 becomes activated during the G1 phase of the cell cycle, and posttranslational modifications modulate its activity. Activation of G-protein coupled receptors (GPCR) by many ligands induces the activation of adenylate cyclases and the production of cAMP, which activates the PKA enzyme. Activated PKA elicits its biological effect by phosphorylating the target proteins containing serine or threonine amino acids in the RxxS/T motif. Since PKA activation negatively regulates cell proliferation, we thought that activated PKA would negatively affect the activity of E2F1. In line with this, when we analyzed the amino acid sequence of E2F1, we found 3 hypothetical consensus PKA phosphorylation sites located at 127-130, 232-235, and 361-364 positions and RYET, RLLS, and RMGS sequences. After showing the binding and phosphorylation of E2F1 by PKA, we converted the codons of Threonine-130, Serine-235, and Serine-364 to Alanine and Glutamic acid codons on the eukaryotic E2F1 expression vector we had previously created. We confirmed the phosphorylation of T130, S235, and S364 by developing monoclonal antibodies against phospho-specific forms of these sites and showed that their phosphorylation is cell cycle-dependent. According to our results, PKA-mediated phosphorylation of E2F1 by PKA inhibits proliferation and glucose uptake and induces caspase-3 activation and senescence.

🔖

Cite This Article

ERTOSUN, M. G., DİLMAC, S., HAPİL, F. Z., TANRİOVER, G., KOKSOY, S., OZES, O. N. (2020). Regulation of E2F1 activity via PKA-mediated phosphorylations. Turkish Journal of Biology, Cilt: 44 - Sayı: 5, 215–229. https://ajindex.com/articles/197907

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Anghileri P, 1999, EXP CELL RES, V250, P510, DOI 10.1006/excr.1999.4531 Aoki I, 2013,
  2. ONCOGENE, V32, P3954, DOI 10.1038/onc.2012.428 BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352 BANDARA LR, 1991,
  3. NATURE, V351, P494, DOI 10.1038/351494a0 Berger B, 2010, NEURO-ONCOLOGY, V12, P894, DOI 10.1093/neuonc/noq051 Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309 Chen D, 2005, CELL DEATH DIFFER, V12, P358, DOI 10.1038/sj.cdd.4401536 Chen G, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.2994 Costanzo V, 1999, CURR BIOL, V9, P903, DOI 10.1016/S0960-9822(99)80395-9 Dali-Youcef N, 2007, P NATL ACAD SCI USA, V104, P10703, DOI 10.1073/pnas.0611568104 DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215 Ertosun MG, 2016, CYTOKINE GROWTH F R, V31, P17, DOI 10.1016/j.cytogfr.2016.02.001 Ferretti AC, 2016,
  4. ONCOTARGET, V7, P17815, DOI 10.18632/oncotarget.7404 Garcia-Alvarez G, 2007, BBA-MOL CELL RES, V1773, P375, DOI 10.1016/j.bbamcr.2006.09.015 Hazar-Rethinam M, 2011, INT J MOL SCI, V12, P8947, DOI 10.3390/ijms12128947 HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501 Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200 Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006 Inoshita S, 1999, KIDNEY INT, V56, P2085, DOI 10.1046/j.1523-1755.1999.00799.x Irwin M, 2000,
  5. NATURE, V407, P645, DOI 10.1038/35036614 Ivanova IA, 2009,
  6. ONCOGENE, V28, P52, DOI 10.1038/onc.2008.354 Jensen J, 2007, BRIT J PHARMACOL, V151, P423, DOI 10.1038/sj.bjp.0707248 Jewell JL, 2019,
  7. ELIFE, V8, DOI 10.7554/eLife.43038 Johnson JL, 2012, CANCER RES, V72, P516, DOI 10.1158/0008-5472.CAN-11-2647 KAELIN WG, 1992,
  8. CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O Kaihara KA, 2015,
  9. DIABETES, V64, P1688, DOI 10.2337/db14-1051 Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006 KOVESDI I, 1986,
  10. CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7 Kumari A, 2015, CELL DEATH DIFFER, V22, P311, DOI 10.1038/cdd.2014.146 Lin WC, 2001, GENE DEV, V15, P1833. Lindstrom MS, 2003,
  11. ONCOGENE, V22, P4993, DOI 10.1038/sj.onc.1206659 Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761 Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887 Medina EA, 2014,
  12. LEUKEMIA, V28, P2080, DOI 10.1038/leu.2014.112 Mohan V, 2012, EXP NEUROL, V237, P477, DOI 10.1016/j.expneurol.2012.07.019 Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201 Ohtani K, 1995, P NATL ACAD SCI USA,